Application of N-acetylcysteine in preparing medicament for preventing decompression sickness caused by fast buoyant ascent escape

A technology of acetylcysteine ​​and decompression sickness, applied in the direction of drug combination, medical formula, respiratory system diseases, etc., can solve problems that have not been used to prevent decompression sickness, and have not been proved by research to prevent decompression sickness, so as to alleviate pathology Change, improve heart function, reduce lung damage and inflammation

Inactive Publication Date: 2014-10-08
NAVY MEDICINE RES INST OF PLA
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no studies have confirmed that this molecule can be used to prevent decompression sickness, and it has not been used to prevent decompression sickness caused by rapid ascent and escape

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of N-acetylcysteine in preparing medicament for preventing decompression sickness caused by fast buoyant ascent escape
  • Application of N-acetylcysteine in preparing medicament for preventing decompression sickness caused by fast buoyant ascent escape
  • Application of N-acetylcysteine in preparing medicament for preventing decompression sickness caused by fast buoyant ascent escape

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Injection drug for experiment: N-acetylcysteine ​​was formulated into a 250 mg / ml solution with physiological saline, and prepared into an injection.

[0021] Experimental animals and grouping: 40 healthy male SD rats, weighing 220-260 g, were purchased from Shanghai Slack Experimental Animal Co., Ltd. SD rats were randomly divided into acetylcysteine ​​250mg / kg prevention group, acetylcysteine ​​500mg / kg prevention group, acetylcysteine ​​1000mg / kg prevention group and normal saline control group, 10 rats in each group.

[0022] Experimental method: 60 minutes before treatment in the prevention group, N-acetylcysteine ​​solution was injected intraperitoneally (injection doses were 250mg / kg, 500mg / kg and 1000mg / kg), and the control group was treated for 60 minutes. Afterwards, the experimental animals were placed in the pressurized chamber for rapid ascending and escaping, and the door was closed, and a self-programmed computer was used to automate the rapid ascending a...

Embodiment 2

[0028] Experimental injection drug: Ashintai (acetylcysteine ​​injection, 20ml, 4g).

[0029] Experimental animals and grouping: 40 healthy male SD rats, weighing 220-260 g, were purchased from Shanghai Slack Experimental Animal Co., Ltd. SD rats were randomly divided into acetylcysteine ​​150mg / kg prevention group, acetylcysteine ​​300mg / kg prevention group, acetylcysteine ​​600mg / kg prevention group and normal saline control group, 10 rats in each group.

[0030] Experimental method: 60 minutes before the treatment of the prevention group, acetylcysteine ​​injection (injection doses were 150mg / kg, 300mg / kg and 600mg / kg) was injected intraperitoneally, and 60 minutes before the treatment of the normal saline control group, the Equal volume of normal saline, and then put the experimental animals in the pressurized chamber for rapid escaping and escape, close the door, and use the self-programmed computer to automate the rapid escaping and escaping procedure, using compressed air...

Embodiment 3

[0034] Injection drug for experiment: use normal saline to make N-acetylcysteine ​​into a 500mg / mL solution, and prepare injection; Ashintai (acetylcysteine ​​injection, 20ml, 4g).

[0035] Experimental animals and grouping: 32 male healthy New Zealand rabbits, weighing 2.3-2.7 kg, were purchased from Shanghai Slack Experimental Animal Co., Ltd. Rabbits were randomly divided into acetylcysteine ​​300mg / kg prevention group (intraperitoneal injection), intraperitoneal injection control group, Ashintai 400mg / kg prevention group (intravenous injection) and ear vein injection control group, 8 rabbits in each group .

[0036] Experimental method: 30 minutes before the treatment of the acetylcysteine ​​300mg / kg prevention group, intraperitoneal injection of N-acetylcysteine ​​solution (injection dose is 300mg / kg), 30 minutes before the treatment of the control group, intraperitoneal injection Equal volume of normal saline, Asixintai 400mg / kg prevention group 15 minutes before treatm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine preparation, and particularly relates to application of N-acetylcysteine in preparing a medicament for preventing decompression sickness caused by fast buoyant ascent escape. N-acetylcysteine is dissolved in normal saline to prepare a 50-500mg/mL injection for use. The dosage of an N-acetylcysteine intraperitoneal injection is 150-1000mg/kg, and the dosage of an N-acetylcysteine intravenous injection is 200-500mg/kg. The N-acetylcysteine is used 16-60 minutes before fast buoyant ascent escape. Experiments prove that the N-acetylcysteine can be used for remarkably inhibiting heart failure caused by myocardial fiber fracture due to air bubbles, improving heart functions and reducing lung injury and inflammation, thus reducing pathologic changes caused by decompression sickness. Experimental data is provided to clinically more reasonable application of N-acetylcysteine to prevention of decompression sickness caused by fast buoyant ascent escape.

Description

technical field [0001] The invention belongs to the field of medicine preparation, and particularly relates to the application of N-acetylcysteine ​​in the preparation of medicines for preventing decompression sickness caused by rapid ascent and escape. Background technique [0002] As one of the main methods for underwater escape of submarine crews generally adopted by the navies of various countries, fast surfacing is to use the principle of no-decompression diving to make the crew escape from the wrecked ship at a large depth. Because of its advantages such as simple equipment, easy method, large escape depth and simple operation, it has been adopted by many countries. However, as the depth deepens, the high-pressure exposure time allowed by the crew is quite limited. If the exposure time is too long due to improper pressure adjustment and other reasons, severe decompression sickness will occur. [0003] The pathogenesis of decompression sickness is that the gas dissolve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61P11/00A61P9/00A61P25/00A61P9/04A61P43/00
Inventor 攸璞方以群王海涛包晓辰王映红姚健李丹陈海庭张师
Owner NAVY MEDICINE RES INST OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap